VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells

  • Authors:
    • Xiao‑Fei Ding
    • Jun Zhou
    • Guang Chen
    • Ying‑Liang Wu
  • View Affiliations

  • Published online on: May 17, 2018     https://doi.org/10.3892/mmr.2018.9038
  • Pages: 1206-1210
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The majority of molecular targets of anticancer agents are limited to a subset of patients, and therefore identification of more specific biomarkers that can be used to improve clinical outcomes is of increasing interest. The present study showed that von Hippel‑Lindau tumor suppressor (VHL) tumor‑suppressor activity may influence the therapeutic response to Aurora kinase A (AURKA) inhibitors in human renal cell carcinoma (RCC). VHL protein (pVHL) expression was evaluated by immunoblotting in the human RCC cell lines CAKI, ACHN, 786‑O, 769‑P and A498. The anti‑tumor activities of alisertib, an AURKA‑specific chemical inhibitor, were detected by Cell Counting Kit‑8 assay in vitro and mouse xenograft model in vivo. Additionally, the VHL‑mediated anti‑tumor activity was assessed in 769‑P and CAKI cells via the loss or gain of VHL. The results revealed that VHL‑deficient 786‑O, 769‑P and A498 cells were sensitive to alisertib. By contrast, alisertib‑resistant CAKI and ACHN cells expressed the wild type VHL gene. In addition, rescue or knockdown of VHL was observed to increase or decrease alisertib anti‑proliferation activity, respectively, in RCC cells. The inverse correlation between the VHL gene expression profile and alisertib sensitivity was further confirmed in human cancer xenografts models. Taken together, these results suggested that VHL loss could potentially serve as a biomarker for predicting the efficacy of AURKA inhibitors.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 18 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding XF, Zhou J, Chen G and Wu YL: VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells. Mol Med Rep 18: 1206-1210, 2018
APA
Ding, X., Zhou, J., Chen, G., & Wu, Y. (2018). VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells. Molecular Medicine Reports, 18, 1206-1210. https://doi.org/10.3892/mmr.2018.9038
MLA
Ding, X., Zhou, J., Chen, G., Wu, Y."VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells". Molecular Medicine Reports 18.1 (2018): 1206-1210.
Chicago
Ding, X., Zhou, J., Chen, G., Wu, Y."VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells". Molecular Medicine Reports 18, no. 1 (2018): 1206-1210. https://doi.org/10.3892/mmr.2018.9038